Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial.

Literature DB >> 31533913

Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial.

Atsushi Tanaka¹, Michio Shimabukuro², Noritaka Machii², Hiroki Teragawa³, Yosuke Okada⁴, Kosuke R Shima⁵, Toshinari Takamura⁵, Isao Taguchi⁶, Itaru Hisauchi⁶, Shigeru Toyoda⁷, Yasushi Matsuzawa⁸, Hirofumi Tomiyama⁹, Minako Yamaoka-Tojo¹⁰, Hisako Yoshida¹¹, Yasunori Sato¹², Yumi Ikehara¹³, Shinichiro Ueda¹⁴, Yukihito Higashi¹⁵, Koichi Node.

Abstract

Entities: Chemical Disease Species

Year: 2019 PMID： 31533913 DOI： 10.2337/dc19-1177

Source DB: PubMed Journal: Diabetes Care ISSN： 0149-5992 Impact factor: 19.112

Keyword Cloud
Cited

× No keyword cloud information.

22 in total

Review 1. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.

Authors: Ralph A DeFronzo; W Brian Reeves; Alaa S Awad
Journal: Nat Rev Nephrol Date: 2021-02-05 Impact factor: 28.314

Review 2. SGLT2 Inhibitors: New Hope for the Treatment of Acute Myocardial Infarction?

Authors: Yu-Jie Wu; Si-Bo Wang; Lian-Sheng Wang
Journal: Am J Cardiovasc Drugs Date: 2022-08-10 Impact factor: 3.283

Review 3. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.

Authors: Volker Vallon; Subodh Verma
Journal: Annu Rev Physiol Date: 2020-11-16 Impact factor: 19.318

Review 4. Hypertension in diabetes care: emerging roles of recent hypoglycemic agents.

Authors: Atsushi Tanaka; Koichi Node
Journal: Hypertens Res Date: 2021-05-14 Impact factor: 3.872

5. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.

Authors: Takayoshi Kanie; Atsushi Mizuno; Yoshimitsu Takaoka; Takahiro Suzuki; Daisuke Yoneoka; Yuri Nishikawa; Wilson Wai San Tam; Jakub Morze; Andrzej Rynkiewicz; Yiqiao Xin; Olivia Wu; Rui Providencia; Joey Sw Kwong
Journal: Cochrane Database Syst Rev Date: 2021-10-25

Review 6. Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.

Authors: Utkarsh Ojha; Lenisse Reyes; Florence Eyenga; Diane Oumbe; Justyna Watkowska; Henock Saint-Jacques
Journal: Am J Cardiovasc Drugs Date: 2021-06-30 Impact factor: 3.571

Review 7. Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis.

Authors: Xiaoling Li; Nina C Weber; Danny M Cohn; Markus W Hollmann; J Hans DeVries; Jeroen Hermanides; Benedikt Preckel
Journal: J Clin Med Date: 2021-05-29 Impact factor: 4.241

8. Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.

Authors: Atsushi Tanaka; Michio Shimabukuro; Hiroki Teragawa; Yosuke Okada; Toshinari Takamura; Isao Taguchi; Shigeru Toyoda; Hirofumi Tomiyama; Shinichiro Ueda; Yukihito Higashi; Koichi Node
Journal: Cardiovasc Diabetol Date: 2021-06-28 Impact factor: 9.951

Review 9. Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms.

Authors: Lei Xiao; Xin Nie; Yanyan Cheng; Nanping Wang
Journal: Cardiovasc Drugs Ther Date: 2021-07-17 Impact factor: 3.727

10. Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin.